Please use this identifier to cite or link to this item:
|Title:||Plasmodium falciparum: Asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant|
Daniel V. Santi
University of California, San Francisco
Thailand National Science and Technology Development Agency
|Keywords:||Immunology and Microbiology|
|Citation:||Experimental Parasitology. Vol.87, No.3 (1997), 245-252|
|Abstract:||The codon for serine residue 108 of the Plasmodium falciparum dihydrofolate reductase gene was replaced with those for the other 19 amino acids. Except for the Lys108mutant, which was not expressed, all other substitutions yielded DHFR mutants which were expressed in Escherichia coli as inactive inclusion bodies. Nine of the mutants - Asn108, Thr108, Gly108, Ala108, Gln108, Cys108, Val108, Leu108, and Met108- yielded active DHFR upon refolding of the protein from the inclusion bodies. The remaining mutants - Ile108, Arg108Pro108, Asp108, His108, Tyr108, Phe108, and Glu108- did not exhibit detectable DHFR activity on refolding. The Asn108mutant had almost unperturbed kinetic parameters but conferred resistance to pyrimethamine and cycloguanil; other active mutants showed poorer DHFR activity. We purified and characterized four mutants which produced highest DHFR activity, i.e., the Gln108, Gly108, Cys108, and Ala108mutants. The mutant enzymes had a k(cat)/K(m) values ranging from 7 to 22% of the wild-type enzyme. While DHFRs from Gly108, Cys108, and Ala108mutants were as susceptible to pyrimethamine and cycloguanil as the wild type, the Gln108mutation conferred high resistance to both inhibitors. Our data suggest that residue 108 is important for antifolate binding, and that the Ser108to Asn108mutation was selected in nature because of (i) the need for only a single base change, (ii) its good activity, and (iii) its resistance to antifolates.|
|Appears in Collections:||Scopus 1991-2000|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.